We describe a case in which the urine based CertNDxTM Bladder Cancer Assay, for mutations in FGFR3, played a pivotal role in diagnosing urothelial cancer in the urinary tract of a patient. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.